HALIFAX, June 18, 2012 /CNW/ - MedMira Inc., (MedMira) (TSXV: MIR), a developer of rapid diagnostic technology and solutions, announced today it has been invited to participate in an exclusive conference taking place June 19-21, 2012, in Norway focused on both military and civilian pre-hospital trauma management. The Remote Damage Control Resuscitation (RDCR) Conference is organized by The Norwegian Naval Special Operation Commando and the Norwegian Air Ambulance Foundation. This three day symposium brings together leading military and civilian medical professionals and researchers in the field to share best practices on pre-hospital trauma and life-threatening haemorrhage management.
"This is the first year we have invited both civilian and military speakers. We recognize that military and civilian pre-hospital trauma management differs in many ways, but there are probably more issues that bring us together than pull us apart. We therefore want both civilian and military perspectives to be presented," said Dr. Geir Strandenes, Senior Medical Officer with the Norwegian Naval Special Operation Commando, a leading researcher in pre-hospital whole blood transfusion, and the principal investigator of the Blood Far Forward research program.
RDCR involves the assessment and treatment of individuals severely wounded in the field, either in a combat situation or a civilian disaster, where evacuation to a hospital is only possible following stabilization by individuals trained in acute trauma care. In far forward settings there are no traditional laboratory screening mechanisms accessible to screen donated blood and previously collected donor blood is not readily available. It is here that advanced healthcare tools like MedMira rapid tests become a critical piece of the RDCR method, where the use of fresh whole blood products may be the only lifesaving option prior to evacuation.
"Connecting with this world class group of medical, scientific and research professionals is an excellent opportunity to further illustrate the unique features of MedMira's advanced rapid diagnostic technology and the benefits it can bring to both combat casualty care and civilian disaster preparedness," said Hermes Chan, CEO, MedMira Inc. "Our ongoing work with the U.S. Army and the Canadian Armed Forces clearly demonstrates that MedMira rapid diagnostics can play a critical role in the treatment of individuals critically wounded in combat. The relationships we have built within these organizations have led us to this opportunity in Norway and we look forward to further collaboration with Dr. Strandenes and his colleagues."
To learn more about the RDCR Conference visit www.wholebloodresearch.com.
MedMira is a leading developer and manufacturer of flow-through rapid diagnostics and technologies. The Company's tests provide hospitals, labs, clinics and individuals with reliable, rapid diagnosis for diseases such as HIV and hepatitis B and C in just three minutes. The company's tests are sold under the Reveal®, Multiplo™ and Miriad brands in global markets. MedMira's rapid flow-through HIV test is the only one in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. MedMira's corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada. For more information visit MedMira's website at www.medmira.com.
This news release contains forward-looking statements, including statements relating to growth in the Company's business, earnings and profitability, and trends in demand for the Company's products, which involve risk and uncertainties and reflect the Company's current expectation regarding future events including statements regarding possible future growth and new business opportunities. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For further information:
Andrea Young, Corporate Communications
Email: [email protected]